|  | Post-treatment | 3-month follow-up | 12-month follow up | |||
---|---|---|---|---|---|---|---|
Mean dif. | d (95%CI) | Mean dif. | d (95%CI) | Mean dif. | d (95%CI) | ||
FFQ-II | |||||||
 | NFA vs. WL | −57.78*** | d = −1.13 (−1.81, −.46) | – |  | – |  |
NFA + TG vs. WL | −66.45*** | d = − 1.27 (− 1.98, −.56) | – |  | – |  | |
NFA vs. NFA + TG | 8.67 | d = .23 (−.46, .93) | −.25 | d = .15 (−.77, 1.07) | 36.90 | .68 (−.24, 1.60) | |
FFS | |||||||
 | NFA vs. WL | − 17.23*** | d = − 1.51 (−.2.13, −.71) | – |  | – |  |
NFA + TG vs. WL | −17.68*** | d = − 1.21 (− 1.92, −.49) | – |  | – |  | |
NFA vs. NFA + TG | .46 | d = .03 (−.66, .73) | −.53 | d = .04 (−.86, .94) | 9.11 | .74 (−.18, 1.66) | |
TB | |||||||
Fear | NFA vs. WL | −.2.86*** | d = − 1.40 (−2.10, −.69) | – |  | – |  |
NFA + TG vs. WL | −3.06*** | d = − 1.25 (− 1.96, −.54) | – |  | – |  | |
NFA vs. NFA + TG | .21 | d = .08 (−.06, .78) | 1.08 | d = .34 (−.01, .68) | 1.77* | .74 (−.16, 1.66) | |
Avoidance | |||||||
 | NFA vs. WL | −3.83*** | d = − 1.48 (− 2.19, −.76) | – |  | – |  |
NFA + TG vs. WL | −3.83*** | d = − 1.21 (− 1.91, −.51) | – |  | – |  | |
NFA vs. NFA + TG | .004 | d = −.02 (−.71, .66) | .66 | d = .35 (−.55, 1.25) | 1.70 | .66 (−.26, 1.57) | |
Belief | |||||||
 | NFA vs. WL | −3.42*** | d = − 1.79 (− 2.54, − 1.04) | – |  | – |  |
NFA + TG vs. WL | −3.95*** | d = − 1.80 (− 2.56, − 1.04) | – |  | – |  | |
NFA vs. NFA + TG | .53 | d = .19 (−.49, .87) | 1.08 | d = .48 (−.43, 1.40) | 2.90* | 1.14 (.18, 2.11) | |
Severity | |||||||
 | NFA vs. WL | −3.07*** | d = − 2.25 (− 3.10, − 1.45) | – |  | – |  |
NFA + TG vs. WL | −3.11*** | d = − 1.69 (− 2.44, −.94) | – |  | – |  | |
NFA vs. NFA + TG | .04 | d = −.01 (−.69, .68) | .42 | d = .36 (−.54, 1.39) | 1.173 | .63 (−.28, 1.55) | |
Improvement | |||||||
 | NFA vs. WL | 1.50*** | d = 2.00 (1.23, 2.46) | – |  | – |  |
NFA + TG vs. WL | 1.53*** | d = 1.71 (.96, 2.46) | – |  | – |  | |
NFA vs. NFA + TG | −.26 | d = −.03 (−.71, .65) | − 1.64 | d = −.51 (− 1.42, .40) | −.58 | −.65 (− 1.56, .27) |